Check the actual OCT scans and scaling, identify traction or neovascular activity, and link treatment to symptoms and progression.
Terminology and draft status
Terminology review is not complete. No new WHO UMD entry verification is claimed; pending entries and limits are recorded in terminology.md.
01Distinguish high from pathologic myopia
High myopia describes refractive severity: IMI 2019 proposes spherical equivalent ≤−6.00 D with accommodation relaxed, at the spectacle plane. Axial length is relevant but the original >26.5 mm example is not a universal definition of pathologic disease. Pathologic myopia concerns characteristic structural complications; posterior staphyloma or myopic maculopathy may occur below that axial length or without high refractive myopia. 1 2 3
The original >20% East-Asian prevalence and 25% complication estimates lack a specified population, age range, denominator and follow-up here. They are not universal current rates or an individual prognosis. Fundus examination, symptoms and selected OCT identify structural complications; neither universal OCT screening for every myopic person nor one compulsory instrument follows from those figures. 1
02Describe curvature and maculopathy separately
A posterior staphyloma is a local outpouching with a smaller curvature radius than the adjacent wall, rather than every globally elongated or posteriorly bowed eye. The historical Curtin types I–V describe wide macular/disc, macular, peripapillary, nasal and inferior patterns; secondary patterns combine them. “Inward bending” alone is not a sufficient geometric definition or proof of an individual detachment risk. 1 3
META-PM categories are 0 no lesion,1 tessellation,2 diffuse chorioretinal atrophy,3 patchy atrophy and 4 macular atrophy. Lacquer cracks, myopic neovascularisation and Fuchs spot are additional plus lesions. This framework and the historical Tokoro system are related but not identical, and categories are not a mandatory sequential cascade. Document atrophy location and associated traction/neovascularisation separately. 1 3
03Check acquisition, scale and artefacts
Common teaching wavelength examples are about 840 nm for spectral-domain OCT(SD-OCT) and 1050 nm for swept-source OCT(SS-OCT). Longer wavelength and lower depth-related sensitivity roll-off can help visualise deep tissue, but performance depends on the model, opacity and acquisition. SS-OCT is useful, not a universal gold standard for every clinical question or cataract. 1
Axial length affects lateral magnification and the actual retinal extent of a nominal scan. The original 6 mm→7 mm example is a possible linear scaling discrepancy, not a universal conversion and not an area measured in millimetres. Use biometry and the actual device correction; compare follow-up scans with consistent geometry and inspect edge degradation before accepting a change. 1
A deep curved posterior contour can produce OCT mirror or truncation artefacts. The zero-delay position is a coherence-depth reference, not the same as optical focus. Reposition the acquisition window and inspect raw B-scans/segmentation; enhanced-depth imaging(EDI) may help selected SD-OCT acquisitions but is not compulsory or sufficient on every model. Widefield photography complements rather than replaces examination of peripheral lesions. 1
04Distinguish traction, cavitation and visible deep tissue
Myopic foveoschisis separates retinal layers into inner and outer patterns under traction and stretch. Assess acuity, symptoms, foveal detachment/hole and progression before considering vitreoretinal surgery; not every schisis requires an operation. Anti-VEGF treats associated active neovascularisation when present, not isolated mechanical schisis. 1
Peripapillary intrachoroidal cavitation (PICC) may appear orange near the myopic conus and can accompany field defects that resemble glaucoma. Locate the cavity and disc-border relationships on OCT; the original “Border Tissue of Jacoby” attribution is unresolved and not a verified diagnostic landmark here. Macular intrachoroidal cavitation(MIC) may create a pseudo-fovea/double-depression appearance; distinguish a choroidal cavity from actual foveal retinal anatomy. 1
Dome-shaped macula(DSM) is a local anterior convexity that can occur within a posteriorly ectatic contour. One orientation may miss it: inspect horizontal, vertical and, when useful, radial scans rather than treating a vertical scan alone as sufficient. Follow associated serous fluid and symptoms; do not assume all fluid is active myopic CNV. 1
Paravascular retinal holes, folds and cysts can accompany vessel-related traction and stretching; verify their layers and relation to the vitreous on raw scans. A tractional inner limiting membrane(ILM) separation must be distinguished from epiretinal membrane and schisis; absence of surface folds alone is not pathognomonic. The proposed “vessels stretch less” explanation is not a diagnostic test. 1
Retina, choroid and sclera may be very thin; the original choroid<10 µm is an extreme example, not a universal threshold or a guaranteed accurate automated measurement. Increased visibility of tissue beyond the sclera does not establish orbital fat or inferior oblique from one OCT band. Correlate anatomy, acquisition and other imaging before naming retrobulbar tissue; the original muscle-insertion attribution remains unverified. 1
05Investigate haemorrhage and treat active myopic neovascularisation
Lacquer cracks are linear breaks in the RPE–Bruch-membrane–choriocapillaris complex and may accompany simple haemorrhage or later neovascularisation. NIR or ICG can improve detection when fundus examination is difficult, but no single modality is always the gold standard. Not every crack inevitably progresses to myopic choroidal neovascularisation(mCNV). 1
Myopic CNV is often type 2, but classify the actual lesion and activity using symptoms, OCT and selected FA/OCT-A. The original 7/10 clear versus 3/10 uncertain diagnoses have no verified denominator. A fixed 2–3 week wait to distinguish lacquer-crack haemorrhage can delay treatment: investigate promptly and treat confirmed active disease; arrange individually safe short review when uncertainty remains. 1
RADIANCE 2014 was a 12 month phaseIII double-masked randomised trial in 277 patients with myopic CNV:106 received ranibizumab guided by visual stability,116 by disease activity and 55 initial vPDT. Control patients could receive ranibizumab/vPDT from month 3. Mean average ETDRS gain over months 1–3 was +10.5/+10.6 versus +2.2 letters(bothP<0.0001). The activity arm was noninferior through month 6(+11.7 versus +11.9, P<0.00001); this does not make all treatment schedules identical. 4
At month 12 gains were +13.8/+14.4/+9.3 letters, but crossover limits the long-term original-comparator contrast. Median 12 month injections were 4.0/2.0/2.0 and leakage resolution 63.8–65.7%; low treatment burden does not mean 1 or 2 injections cure everyone permanently. No observed endophthalmitis, myocardial infarction or death in this trial is not zero risk. Complete methods, attrition, protocol and confidence intervals require full-report appraisal; monitor recurrent activity with an individual PRN plan and the actual drug label. 4
06Match surveillance to the actual lesion and glaucoma risk
The original annual dilated examination/biometry and 3–6 month lesion reviews are teaching examples, not one verified German rule for all myopic patients. Follow symptoms, axial/refractive change, peripheral retina, macular traction and neovascular activity. Use a shorter interval or urgent review when the findings change rather than waiting for the scheduled date. 1
Tilted discs, peripapillary atrophy, scan scaling and segmentation can distort standard glaucoma OCT classifications in high myopia. Inspect the scans and relate disc/RNFL findings to reproducible visual fields and longitudinal change. A PICC-associated defect does not rule out coexisting glaucoma, and an abnormal colour code alone does not prove it. 1
| Lesion | Clinical concept | Selected action | Imaging | Limits / pitfalls |
|---|---|---|---|---|
| Myopic foveoschisis | Inner/outer retinal splitting | Consider surgery for selected symptomatic/progressive disease | OCT, including SS-OCT when useful | Anti-VEGF is not treatment for isolated mechanical schisis. |
| mCNV | Often type 2 neovascularisation | Individual anti-VEGF activity-guided 1+PRN plan | OCT and selected angiography | Original 2–3 week observation is not mandatory; do not delay active disease treatment. |
| Dome-shaped macula | Local anterior convexity | Monitor fluid and symptoms by cause | Horizontal/vertical and selected radial OCT | One scan orientation may miss the dome; vertical alone is not sufficient. |
| PICC | Peripapillary intrachoroidal cavity | Assess glaucoma differential and coexistence | OCT plus visual fields | Original Border Tissue of Jacoby attribution unresolved; a field defect is not specific. |
| Lacquer cracks | Breaks in the Bruch/RPE/choriocapillaris complex | Explain possible haemorrhage/mCNV risk | Selected NIR/ICG and multimodal correlation | May be subtle on fundoscopy; not every crack leads to mCNV. |
| Scaling | Nominal 6 mm may cover 7 mm in a particular eye/device | Use biometry and actual magnification correction | Check SS/SD-OCT acquisition and follow-up geometry | Linear distance, not area or universal conversion; inspect scan edges. |
What are the main learning points?
Check the actual OCT scans and scaling, identify traction or neovascular activity, and link treatment to symptoms and progression.
When is assessment urgent?
New distortion, central scotoma, sudden visual decline, flashes, floaters or a curtain-like field defect needs prompt assessment; do not postpone suspected active neovascularisation for a fixed observation interval.
References and access status
- 1Immutable original export; own full high-myopia imaging export
Complete export read; original attribution and any recording/transcript or appointment not independently verified.
- 2IMI 2019 defining and classifying myopia; PMID 30817826
Indexed abstract and selected section 4.4 definitions read 17 November 2026; full report, methodology and underlying studies unread.
- 3IMI 2021 pathologic myopia; PMID 33909033
Indexed abstract and selected definition/staphyloma/META-PM classification text read 17 November 2026; not full report or actual figures, classification validation or every underlying study.
- 4RADIANCE 2014 ranibizumab versus vPDT in myopic CNV; PMID 24326106
Complete indexed primary abstract read 17 November 2026; full methods, attrition, protocol/supplements and confidence-interval appraisal unread. Comparator crossover from month 3 limits later contrast.
Original lecture link
For patients
Strong short-sightedness and damage at the back of the eye are different findings. Imaging helps identify the cause of new symptoms; not every structural change needs the same treatment.
Examination and selected tests guide individual treatment and follow-up; this educational text cannot replace your own assessment.
New distortion, central scotoma, sudden visual decline, flashes, floaters or a curtain-like field defect needs prompt assessment; do not postpone suspected active neovascularisation for a fixed observation interval.
New distortion, central scotoma, sudden visual decline, flashes, floaters or a curtain-like field defect needs prompt assessment; do not postpone suspected active neovascularisation for a fixed observation interval.